Browsing by Subject "Cyclic AMP Response Element-Binding Protein"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Inhibition of Cell Proliferation through Regulated Intramembrane Proteolysis of CREB3L1(2012-07-10) Denard, Bray Standard; Ye, JinCREB3L1/OASIS is a cellular transcription factor synthesized as a membrane- bound precursor and activated by regulated intramembrane proteolysis in response to stimuli like ER stress. By comparing gene expression between Huh7 subclones that are permissive for hepatitis C virus (HCV) replication versus the non-permissive parental Huh7 cells, we identified CREB3L1 as a host factor that inhibits proliferation of virus-infected cells. Upon infection with diverse DNA and RNA viruses, including murine gamma-herpesvirus 68, HCV, West Nile virus (WNV), and Sendai virus, CREB3L1 was proteolytically cleaved, allowing its NH2 terminus to enter the nucleus and induce multiple genes encoding inhibitors of the cell cycle to block cell proliferation. Consistent with this, we observed a necessity for CREB3L1 expression to be silenced in proliferating cells that harbor replicons of HCV or WNV. Our results indicate that CREB3L1 may play an important role in limiting virus spread by inhibiting proliferation of virus-infected cells. Doxorubicin is used extensively for chemotherapy of diverse types of cancer, yet the mechanism through which it inhibits proliferation of cancer cells remains unclear. Here we report that doxorubicin stimulates de novo synthesis of ceramide, which in turn activates CREB3L1, a transcription factor synthesized as a membrane-bound precursor. Doxorubicin stimulates proteolytic cleavage of CREB3L1 by Site-1 Protease and Site-2 Protease, allowing the NH2-terminal domain of CREB3L1 to enter the nucleus where it activates transcription of genes encoding inhibitors of the cell cycle, including p21. Knockdown of CREB3L1 mRNA in human hepatoma Huh7 cells and immortalized human fibroblast SV589 cells conferred increased resistance to doxorubicin, whereas overexpression of CREB3L1 in human breast cancer MCF-7 cells markedly enhanced the sensitivity of these cells to doxorubicin. These results suggest that measurement of CREB3L1 expression may be a useful biomarker in identifying cancer cells sensitive to doxorubicin. [Keywords: CRE34, HCV, RIP, Doxorubicin, ceramide, myriocin, proliferation, virus, p21, collagen]Item Understanding the Molecular Basis for FGF15/19 and FGF21 Actions on Energy Homeostasis(2012-07-09) Boney-Montoya, Jamie; Kliewer, Steven A.Insulin and glucagon have long been known to play essential roles in controlling energy balance during the fed and fasted states, respectively. Recently, additional metabolic hormones have been discovered within a subfamily of the fibroblast growth factor superfamily. The FGF15/19 subfamily is composed of atypical FGFs lacking the heparin-binding domain, which enables them to act in an endocrine fashion by diffusing away from their tissues of origin. They signal through cell-surface receptors complexed with beta-Klotho, a membrane-spanning protein, to mediate signaling cascades that lead to physiological responses. One member, FGF19, causes reduced glucose and insulin levels with enhanced insulin sensitivity when expressed in transgenic mice. Another member, FGF21, has been shown to act as an insulin sensitizer pharmacologically by improving glucose tolerance and reducing insulin. The prevalence of metabolic disorders (e.g. type 2 diabetes) in today’s society has led to the investigation of these two endocrine FGFs for use in a clinical setting. However, the mechanisms underlying these responses have not been characterized. // To elucidate the mechanisms utilized by FGF15/19, we used several animal models to show a role for FGF15/19 in regulating hepatic glucose production. Like insulin, FGF15/19 represses gluconeogenesis. Specifically, FGF15/19 inhibits expression of the transcriptional coactivator PGC1-alpha, a key regulator of gluconeogenic gene expression. The repressive effect of FGF15/19 on gluconeogenic gene expression is lost when PGC1-alpha is overexpressed. FGF15/19 causes the dephosphorylation and inactivation of the transcription factor CREB, thereby blunting its ability to bind and induce the PGC1-alpha promoter. The results demonstrated that FGF15/19 works subsequent to insulin as a postprandial regulator of gluconeogenesis through inhibition of the CREB/ PGC1-alpha pathway. // To fully understand the effects of FGF21, we began studying the downstream kinase signaling cascades and the protein substrates affected by this hormone. Utilizing stable isotope labeling of amino acids in cell culture (SILAC), an unbiased phosphoproteomic profile was obtained of potential FGF21 targets in rat H4IIE hepatoma cells. One of the most highly regulated targets was FetuinA, which was dephosphorylated by FGF21 treatment. FetuinA is an inhibitor of insulin receptor signaling and the FetuinA knockout mouse exhibits aberrant glucose homeostatsis. Our in vitro data suggested a relationship between FGF21 and FetuinA in regulating insulin sensitivity but further exploration lead to the conclusion that FGF21 was not directly regulating FetuinA in vivo. // Taken together, the important role of FGF15/19 and FGF21 in regulating carbohydrate metabolism as well as their pharmacological actions makes them attractive drug candidates for metabolic diseases. However, further study will be required to determine their molecular mechanisms more completely and their long-term efficacy in the clinic. [Keywords: FGF15/19, FGF21, gluconeogenesis, CREB, PGCI-alpha, Fetuin-A, phosphorylation, beta-klotho]